Evidence map›Paper›PMID 25120083›Full record

ArticleArquivos brasileiros de cardiologia2014

Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.

Lisiane Smiderle, Luciana O Lima, Mara Helena Hutz, Cézar Roberto Van der Sand, Luiz Carlos Van der Sand, Maria Elvira Wagner Ferreira, Renan Canibal Pires, Silvana Almeida, Marilu Fiegenbaum

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arquivos brasileiros de cardiologia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. [Molecular pharmaceutics · 2021
    Article
  7. Article
  8. Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils.Journal of clinical and diagnostic research : JCDR · 2017
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lisiane SmiderleUniversidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Luciana O LimaUniversidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Mara Helena HutzUniversidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Cézar Roberto Van der SandCentro de Diagnóstico Cardiológico, Porto Alegre, RS, Brazil.
Luiz Carlos Van der SandCentro de Diagnóstico Cardiológico, Porto Alegre, RS, Brazil.
Maria Elvira Wagner FerreiraCentro de Diagnóstico Cardiológico, Porto Alegre, RS, Brazil.
Renan Canibal PiresCentro de Diagnóstico Cardiológico, Porto Alegre, RS, Brazil.
Silvana AlmeidaUniversidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Marilu FiegenbaumUniversidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Hospital de Clínicas de Porto Alegre · BRUniversidade Federal de Ciências da Saúde de Porto Alegre · BRUniversidade Federal do Rio Grande do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDyslipidemia is the primary risk factor for cardiovascular disease, and statins have been effective in controlling lipid levels. Sex differences in the pharmacokinetics and pharmacodynamics of statins contribute to interindividual variations in drug efficacy and toxicity.

objectiveTo evaluate the presence of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin treatment.

methodsLipid levels of 495 patients (331 women and 164 men) were measured at baseline and after 6 ± 3 months of simvastatin/atorvastatin treatment to assess the efficacy and safety profiles of both drugs.

resultsWomen had higher baseline levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) compared with men (p < 0.0001). After treatment, women exhibited a greater decrease in plasma TC and LDL-C levels compared with men. After adjustment for covariates, baseline levels of TC and LDL-C influenced more than 30% of the efficacy of lipid-lowering therapy (p < 0.001), regardless of sex. Myalgia [with or without changes in creatine phosphokinase (CPK) levels] occurred more frequently in women (25.9%; p = 0.002), whereas an increase in CPK and/or abnormal liver function was more frequent in in men (17.9%; p = 0.017).

conclusionsOur results show that baseline TC and LDL-C levels are the main predictors of simvastatin/atorvastatin therapy efficacy, regardless of sex. In addition, they suggest the presence of sexual dimorphism in the safety of simvastatin/atorvastatin. The effect of sex differences on receptors, transporter proteins, and gene expression pathways needs to be better evaluated and characterized to confirm these observations.

Indexed as

Sex FactorsAdultAgedAged, 80 and overAnticholesteremic AgentsAtorvastatinBrazilCholesterolCreatine KinaseFemaleHeptanoic AcidsHumansHypercholesterolemiaHypolipidemic AgentsLipoproteins, HDLLipoproteins, LDLAnticholesteremic AgentsAtorvastatinCholesterolCreatine KinaseHeptanoic AcidsHypolipidemic AgentsLipoproteins, HDLLipoproteins, LDLPyrrolesSimvastatin

Identifiers

PMID25120083
PMCPMC4126759
OpenAlexW2074047862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.